ADMA Biologics has received FDA approval for a groundbreaking production process that increases immune globulin yields by approximately 20% from the same plasma volume, becoming the first U.S. company to achieve this regulatory milestone.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.